Tesamorelin

Synthetic growth hormone-releasing hormone (GHRH).  Here are its key benefits based on clinical evidence:

1.  Reduction of Visceral Fat: Tesamorelin stimulates growth hormone secretion, which reduces visceral adipose tissue (VAT). Clinical trials showed a 15-20% decrease in VAT over 26-52 weeks in HIV-associated lipodystrophy patients, improving waist circumference and abdominal appearance without significantly affecting subcutaneous fat.

2.  Improved Metabolic Health: By reducing VAT, tesamorelin enhances insulin sensitivity and lowers triglycerides. Studies report better lipid profiles (e.g., reduced LDL cholesterol) and decreased liver fat, potentially lowering risks of cardiovascular disease and type 2 diabetes in treated patients.

3.  Enhanced Body Composition: Tesamorelin may improve lean muscle mass and overall body composition due to increased growth hormone levels, supporting physical function and aesthetics in those with excess abdominal fat.

4.  Better Quality of Life: Patients report improved self-image and reduced discomfort from abdominal fat accumulation, particularly in HIV lipodystrophy, with benefits persisting with continued use.

5.  Potential Cognitive Benefits: Emerging research suggests tesamorelin may improve cognitive function in older adults or those with mild cognitive impairment by boosting growth hormone and IGF-1 levels, though this is not an approved use and requires further study.